Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clozapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 10/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 9/20 | 1.00 |
| ▸ | DRD4 | P21917 | 7/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clozapine SCHEMBL8397 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL20876213 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29360001 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL5501558 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29433929 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL28700741 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL28648626 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29180214 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL140458 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29041024 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250250244-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | H LUNDBECK AS (DK) | 2025-08-07 | — | — | US | disclosed |
| US-11918590-B2 | Stable extended release pharmaceutical composition of clozapine | INTAS PHARMACEUTICALS LTD. (IN) | 2024-03-05 | — | — | US | disclosed |
| EP-3512521-B1 | EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF CLOZAPINE | INTAS PHARMACEUTICALS LTD (IN) | 2023-08-02 | — | — | EP | disclosed |
| US-20230181595-A1 | STABLE EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF CLOZAPINE | INTAS PHARMACEUTICALS LTD. (IN) | 2023-06-15 | — | — | US | disclosed |
| EP-4135721-A1 | TREATMENT OF ADVERSE EFFECTS CAUSED BY ATYPICAL ANTIPSYCHOTICS | Shenzhen Profound View Pharmaceutical Technology Co., Ltd. (CN) | 2023-02-22 | — | — | EP | disclosed |
| CN-111568922-B | Treatment of atypical antipsychotic-induced adverse reactions | 深圳深见医药科技有限公司 | 2022-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250250244-A1 | DEUTERATED 1-PIPERAZINO-3-PHENYL INDANES FOR TREATMENT OF SCHIZOPHRENIA | HTR2C, DRD2, HTR2A | DRD2 2/4885HTR2A 3/4885CHRM1 62/4885 |
| US-11918590-B2 | Stable extended release pharmaceutical composition of clozapine | SLC18A1, SLC18A2, CYP2C19 | DRD2 8/4885HTR2A 11/4885CHRM1 424/4885 |
| US-20230181595-A1 | STABLE EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF CLOZAPINE | SLC18A1, SLC18A2, CYP2C19 | DRD2 8/4885HTR2A 11/4885CHRM1 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.